Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
August 20, 2014 13:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
August 15, 2014 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
July 01, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
June 18, 2014 10:39 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
June 02, 2014 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 2, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Second Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
May 15, 2014 19:03 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces First Quarter Fiscal Year 2014 Financial Results
February 14, 2014 17:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 14, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Process Improvements and Positive 18 Month Stability Results for AEOL 10150 in New Formulation
February 13, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 13, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
90% reduction in manufacturing cost of drug substance achieved;...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal Model of Lung Radiation Exposure; Models Developed for Pivotal Efficacy Studies
February 10, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Feb 10, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Three papers published in Health Physics, Volume 106, Number 1 (January 2014)
...
Aeolus Receives Orphan Drug Designation for AEOL 10150 From U.S. FDA
January 23, 2014 10:52 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jan 23, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...